Corporate Investments In Biotech
This article was originally published in Start Up
Executive Summary
Public biotechs now rely as much as ever on institutional funding, as public equity markets remain chilly. But, for a step-up in valuation, biotechs can only turn to corporate investors, who might be persuaded to pay a strategic premium.